NCT07829445

Brief Summary

To determine whether special laboratory tests, called genomic sequencing, can identify specific subtypes of LBCL and provide information that may help guide treatment decisions.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
29mo left

Started Feb 2027

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 17, 2026

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 21, 2026

Completed
5 months until next milestone

Study Start

First participant enrolled

February 25, 2027

Expected
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2027

2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2029

Last Updated

September 21, 2026

Status Verified

September 1, 2026

Enrollment Period

4 months

First QC Date

September 17, 2026

Last Update Submit

September 17, 2026

Conditions

Precision TreatmentLBCLComprehensive Genomic

Outcome Measures

Primary Outcomes (1)

  • Safety and adverse events (AEs)

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

    Through study completion; an average of 1 year.

Study Arms (3)

ABC_Subtype

Other: Standard of Care (SOC)

DZsig_Subtype

Other: Standard of Care (SOC)

Other GCB_Subtype

Other: Standard of Care (SOC)

Interventions

Standard of Care (SOC)OTHER

Standard of care

ABC_SubtypeDZsig_SubtypeOther GCB_Subtype

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

MD Anderson Cancer Center

You may not qualify if:

  • Known central nervous system (CNS) disease (cases concerning for CNS involvement should be evaluated with MRI and lumbar puncture)
  • Any baseline characteristics that in the opinion of the treating physician would preclude patients from receiving standard-of-care anthracycline-based treatment
  • Participation (or planning to participate) in any therapeutic clinical trials for lymphoma during the planned treatment course. Note, patients who become eligible for other studies based on inadequate response, toxicity to therapy, or other reasons that arise after the initiation of standard therapy on this study are permitted to pursue those alternative trials as appropriate. Participation in other non-therapeutic and/or observational studies are permitted.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UT MD Anderson Cancer Center

Houston, Texas, 77030, United States

Location

Related Links

MeSH Terms

Interventions

Standard of Care

Intervention Hierarchy (Ancestors)

Quality Indicators, Health CareQuality of Health CareHealth Services AdministrationHealth Care Quality, Access, and Evaluation

Study Officials

  • Dai Chihara, MD

    UT MD Anderson Cancer Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Dai Chihara, MD

CONTACT

713-563-4354JMDennison@mdanderson.org

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 17, 2026

First Posted

September 21, 2026

Study Start (Estimated)

February 25, 2027

Primary Completion (Estimated)

June 30, 2027

Study Completion (Estimated)

June 30, 2029

Last Updated

September 21, 2026

Record last verified: 2026-09

Locations

US(1)